About: Seroprevalence of anti-SARS-CoV-2 IgG antibody in hospitalized patients in a tertiary referral center in North India

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Seroprevalence of anti-SARS-CoV-2 IgG antibody in hospitalized patients in a tertiary referral center in North India Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Seroprevalence of anti-SARS-CoV-2 IgG antibody in hospitalized patients in a tertiary referral center in North India
Creator	Nischal, Neeraj Soneja, Manish Wig, Naveet Agarwal, Ayush Agarwal, Shubham Arora, Umang Batra, Gaurav Bhavesh, M Chaithra, R Chattopadhyay, Souvick Datt Upadhyay, Ashish Gagantej, Kumar, Kartikeyan Mehdi, Farha Nagpal, Chitrakshi Pandey, R Ray, Animesh Sahni, Shubham Singh Jadon, Ranveer Singh, Komal Vikram, Naval
Source	MedRxiv
abstract	Background: Seroprevalence of IgG antibodies against SARS-CoV-2 is an important tool to estimate the true extent of infection in a population. However, seroprevalence studies have been scarce in South East Asia including India, which, as of now, carries the third largest burden of confirmed cases in the world. The present study aimed to estimate the seroprevalence of the anti-SARS-CoV-2 IgG antibody among hospitalized patients at one of the largest government hospital in India. Method: This cross-sectional study, conducted at a tertiary care hospital in North India, recruited consecutive patients who were negative for SARS-CoV-2 by RT-PCR or CB-NAAT. Anti-SARS-CoV-2 IgG antibody levels targeting recombinant spike receptor-binding domain (RBD) protein of SARS CoV-2 were estimated in serum samples by the ELISA method. Results: A total of 212 hospitalized patients were recruited in the study with mean age (+/-SD) of 41.2 (+/-15.4) years and 55% male population. Positive serology against SARS CoV-2 was detected in 19.8% patients(95% CI 14.7-25.8). Residency in Delhi conferred a higher frequency of seropositivity 26.5% (95% CI 19.3-34.7) as compared to that of other states 8% (95% CI 3.0-16.4) with p-value 0.001. No particular age groups or socio-economic strata showed a higher proportion of seropositivity. Conclusion: Around, one-fifth of hospitalized patients, who were not diagnosed with COVID-19 before, demonstrated seropositivity against SARS-CoV-2. While there was no significant difference in the different age groups and socio-economic classes; residence in Delhi was associated with increased risk (relative risk of 3.62, 95% CI 1.59-8.21) Key Words: SARS-CoV-2 IgG Antibody, Seroprevalence, Hospitalized patient, COVID-19
has issue date	2020-08-25(xsd:dateTime)
bibo:doi	10.1101/2020.08.22.20179937
has license	medrxiv
sha1sum (hex)	b4cf5cba81dac5d3cf0683d83b056c1a4a0d04e1
schema:url	https://doi.org/10.1101/2020.08.22.20179937
resource representing a document's title	Seroprevalence of anti-SARS-CoV-2 IgG antibody in hospitalized patients in a tertiary referral center in North India
resource representing a document's body	covid:b4cf5cba81dac5d3cf0683d83b056c1a4a0d04e1#body_text
is schema:about of	named entity 'infection' named entity 'studies' named entity 'antibody' named entity 'ONE OF' named entity 'CARRIES' named entity 'LARGEST' named entity 'ESTIMATE' named entity 'INDIA' named entity 'IgG' named entity 'antibody' named entity 'SARS-CoV-2' named entity 'tool' named entity 'infection' named entity 'India' named entity 'North India' named entity 'tertiary referral center' named entity 'preprint' named entity 'preprint' named entity 'ICU' named entity 'NAAT' named entity 'sero' named entity 'medRxiv' named entity 'COVID' named entity 'Asian' named entity 'cross-sectional study' named entity 'preprint' named entity 'Delhi' named entity 'IgG' named entity 'Antibody' named entity 'SARS-CoV-2' named entity 'health care workers' named entity 'SARS-CoV-2' named entity 'written consent' named entity 'SARS-CoV-2' named entity 'Wuhan' named entity 'Nucleic acid amplification test' named entity 'preprint' named entity 'medRxiv' named entity 'statistically significant' named entity 'Iran' named entity 'preprint' named entity 'vaccination' named entity 'medRxiv' named entity 'CC-BY-ND' named entity 'preprint' named entity 'medRxiv' named entity 'statistically significant' named entity 'medRxiv' named entity 'IFR' named entity 'Uttar Pradesh' named entity 'June 9' named entity 'CC-BY-ND' named entity 'vaccination' named entity 'COVID-19 pandemic' named entity 'NAAT' named entity 'BCG' named entity 'asymptomatic' named entity 'seroprevalence' named entity 'Delhi' named entity 'Uttar Pradesh' named entity 'preprint' named entity 'virus' named entity 'seroprevalence' named entity 'serum' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software